Nektar Therapeutics
Every calculator, already run for NKTR
Open the full toolkit →You have the numbers on NKTR. Get the argument.
A written report on which of these readings actually decide the outcome for Nektar Therapeutics, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering NKTRAnalyst Price Target Disagreement for Nektar Therapeutics
Wall Street's bull case implies +186% from the current price; the bear case implies -3%. A 189% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for NKTR
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfi…
NKTR — frequently asked
Is NKTR a buy right now?
Wall Street's consensus rating on Nektar Therapeutics is Strong Buy across 12 analysts, with a mean price target of $144.40 (+115% vs. the current $67.10). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is NKTR's next earnings date?
Nektar Therapeutics is next scheduled to report earnings around Nov 12, 2026. A full NKTR research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Nektar Therapeutics?
Analysts covering Nektar Therapeutics (NKTR) range from a bear-case target of $65.00 to a bull-case high of $192.00, with a mean consensus target of $144.40 across 10 analysts. The spread of $127.00 (189% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Nektar Therapeutics against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Nektar Therapeutics
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full NKTR research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Nektar Therapeutics, in minutes. 3 free reports included with every account — no credit card required.